NDLI: Current and future therapies for hepatitis C virus infection: from viral proteins to host targets

Content Provider	Springer Nature Link
Author	Imran, Muhammad Manzoor, Sobia Khattak, Nasir Mahmood Khalid, Madiha Ahmed, Qazi Laeeque Parvaiz, Fahed Tariq, Muqddas Ashraf, Javed Ashraf, Waseem Azam, Sikandar Ashraf, Muhammad
Copyright Year	2013
Abstract	Hepatitis C virus (HCV) infection is the most important problem across the world. It causes acute and chronic liver infection. Different approaches are in use to inhibit HCV infection, including small organic compounds, siRNA, shRNA and peptide inhibitors. This review article summarizes the current and future therapies for HCV infection. PubMed and Google Scholar were searched for articles published in English to give an insight into the current inhibitors against this life-threatening virus. HCV NS3/4A protease inhibitors and nucleoside/nucleotide inhibitors of NS5B polymerase are presently in the most progressive stage of clinical development, but they are linked with the development of resistance and viral breakthrough. Boceprevir and telaprevir are the two most important protease inhibitors that have been approved recently for the treatment of HCV infection. These two drugs are now the part of standard-of-care treatment (SOC). There are also many other drugs in phase III of clinical development. When exploring the various host-cell-targeting compounds, the most hopeful results have been demonstrated by cyclophilin inhibitors. The current SOC treatment of HCV infection is Peg-interferon, ribavirin and protease inhibitors (boceprevir or telaprevir). The future treatment of this life-threatening disease must involve combinations of therapies hitting multiple targets of HCV and host factors. It is strongly expected that the near future, treatment of HCV infection will be a combination of direct-acting agents (DAA) without the involvement of interferon to eliminate its side effects.
Starting Page	831
Ending Page	846
Page Count	16
File Format	PDF
ISSN	03048608
Journal	Archives of Virology
Volume Number	159
Issue Number	5
e-ISSN	14328798
Language	English
Publisher	Springer Vienna
Publisher Date	2013-08-25
Publisher Place	Vienna
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Virology Medical Microbiology Infectious Diseases
Content Type	Text
Resource Type	Article
Subject	Virology Medicine

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Erratum to: Current and future therapies for hepatitis C virus infection: from viral proteins to host targets

Erratum to: Current and future therapies for hepatitis C virus infection: from viral proteins to host targets

Recombinant human antibodies specific for hepatitis C virus proteins

Subcellular localization of hepatitis C viral proteins in mammalian cells

Hepatitis C virus genotype diversity in Shanghai, China

Influence of hepatitis C virus infection on the mortality of antiretroviral-treated patients with HIV disease

Expression, immunogenicity and diagnostic value of envelope proteins from an Egyptian hepatitis C virus isolate

Activation of endoplasmic reticulum stress response by hepatitis C virus proteins

Hepatitis C virus infection and mutations of mannose-binding lectin gene MBL

Current and future therapies for hepatitis C virus infection: from viral proteins to host targets

Similar Documents

Erratum to: Current and future therapies for hepatitis C virus infection: from viral proteins to host targets

Erratum to: Current and future therapies for hepatitis C virus infection: from viral proteins to host targets

Recombinant human antibodies specific for hepatitis C virus proteins

Subcellular localization of hepatitis C viral proteins in mammalian cells

Hepatitis C virus genotype diversity in Shanghai, China

Influence of hepatitis C virus infection on the mortality of antiretroviral-treated patients with HIV disease

Expression, immunogenicity and diagnostic value of envelope proteins from an Egyptian hepatitis C virus isolate

Activation of endoplasmic reticulum stress response by hepatitis C virus proteins

Hepatitis C virus infection and mutations of mannose-binding lectin gene MBL

Current and future therapies for hepatitis C virus infection: from viral proteins to host targets